COCHW
Envoy Medical, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.04
−1.74%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 207.0K | 241.0K | 225.0K | 316.0K | 237.0K |
| Cost of Revenue | 1.0M | 874.0K | 742.0K | 789.0K | 498.0K |
| Gross Profit | (798.0K) | (633.0K) | (517.0K) | (473.0K) | (261.0K) |
| Operating Expenses | |||||
| R&D Expense | 14.0M | 12.5M | 10.2M | 9.0M | 5.0M |
| SG&A Expense | 8.8M | 9.2M | 8.6M | 8.9M | 3.5M |
| General & Admin Expense | 8.0M | 7.9M | 6.8M | 7.3M | 2.6M |
| Selling & Marketing Expense | 846.0K | 1.2M | 1.7M | 1.7M | 885.0K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 22.8M | 21.6M | 18.7M | 17.9M | 8.4M |
| Cost and Expenses | 23.8M | 22.5M | 19.5M | 18.7M | 8.9M |
| Operating Income (EBIT) | (23.6M) | (22.3M) | (19.3M) | (18.4M) | (8.7M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 471.0K | 1.6M | 816.0K | — | — |
| Net Interest Income | (471.0K) | (1.6M) | (816.0K) | — | — |
| Other Non-Op Income/Expense | 220.0K | (1.5M) | (1.5M) | (11.6M) | (7.2M) |
| Non-Operating Income (excl Interest) | (1.5M) | (104.0K) | 723.0K | 11.6M | 7.2M |
| EBT (Pre-Tax Income) | (23.4M) | (23.8M) | (20.8M) | (29.9M) | (15.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (23.4M) | (23.8M) | (20.8M) | (29.9M) | (15.9M) |
| Earnings from Cont. Ops | (23.4M) | (23.8M) | (20.8M) | (29.9M) | (15.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (28.5M) | (23.8M) | (28.0M) | (31.3M) | (15.9M) |
| Per Share | |||||
| Basic EPS | ($0.67) | ($1.23) | ($1.49) | ($2.54) | ($1.57) |
| Diluted EPS | ($0.67) | ($1.23) | ($1.49) | ($2.54) | ($1.57) |
| Revenue Per Share | $0.00 | $0.01 | $0.01 | $0.03 | $0.02 |
| Shares | |||||
| Basic Shares Outstanding | 104.0M | 23.3M | 18.8M | 12.6M | 10.2M |
| Diluted Shares Outstanding | 104.0M | 23.3M | 18.8M | 12.6M | 10.2M |
| Profitability Metrics | |||||
| EBITDA | (21.9M) | (21.9M) | (19.8M) | (29.8M) | (15.8M) |
| D&A | 229.0K | 302.0K | 173.0K | 133.0K | 75.0K |
| EBIT | (22.1M) | (22.2M) | (20.0M) | (29.9M) | (15.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026